Cardiovascular Risk Reduction in Atrial Fibrillation Trial
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Atrial Fibrillation
- Hypertension
- Type
- Interventional
- Phase
- Not Applicable
- Design
- Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: Single (Outcomes Assessor)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
The CRAFT trial will include approximately 6000 AF patients with home SBP 125-154 mmHg and at least another cardiovascular risk factor. The trial aims to compare the effects of randomization to a treatment program of an intensive SBP goal (target home SBP <120mmHg) with randomization to a treatment ...
The CRAFT trial will include approximately 6000 AF patients with home SBP 125-154 mmHg and at least another cardiovascular risk factor. The trial aims to compare the effects of randomization to a treatment program of an intensive SBP goal (target home SBP <120mmHg) with randomization to a treatment program of a standard goal (target home SBP <135mmHg). The primary hypothesis is that cardiovascular event rates will be lower in the intensive arm. Participants will be recruited over a 3-year period at approximately 100 to 150 clinical centres and the first patient will be followed for up to 5 years.
Tracking Information
- NCT #
- NCT04347330
- Collaborators
- Heart Health Research Centre
- The George Institute for Global Health, China
- The George Institute for Global Health, Australia
- Fukuoka University
- Investigators
- Principal Investigator: Changsheng Ma, Doctor Beijing Anzhen Hospital Principal Investigator: Craig S Anderson, Doctor The George Institute for Global Health, China; Heart Health Research Centre Principal Investigator: Jianzeng Dong, Doctor Beijing Anzhen Hospital; The First Affiliated Hospital of Zhengzhou University
Get Well Soon